Investment Rating - The report maintains a "Recommended" rating for the company [1][5]. Core Insights - The company reported a revenue of 1.247 billion yuan for the first half of 2025, a year-on-year decrease of 3.64%, while the net profit attributable to shareholders increased by 10.01% to 445 million yuan [3]. - The gross profit margin and net profit margin improved significantly, reaching 51.26% and 35.97% respectively, with increases of 3.78 percentage points and 4.32 percentage points year-on-year, driven by higher contributions from high-margin businesses in life sciences, metal resources, and ultra-pure water [3]. - The company plans to invest 1.15 billion yuan in building a high-end materials industrial park in Pucheng to enhance its life sciences segment [3]. Financial Performance Summary - For the first half of 2025, the company achieved a net cash flow of 288 million yuan, reflecting a positive trend [3]. - The company’s asset-liability ratio stood at 36.30%, a decrease of 3.73 percentage points year-on-year, indicating low debt risk [3]. - The company’s revenue from adsorption materials was 1.007 billion yuan, a year-on-year increase of 3.40%, with significant growth in the water treatment, life sciences, and metal resources segments [3]. Future Projections - The company is projected to achieve net profits of 1.014 billion yuan, 1.209 billion yuan, and 1.527 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 26.98X, 22.63X, and 17.92X [5][4]. - Revenue is expected to grow at rates of 17.66%, 22.90%, and 17.27% for the years 2025, 2026, and 2027 respectively [4][7].

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6]. Core Views - The company reported a revenue of 2.554 billion yuan in 2024, a year-on-year increase of 2.6%, and a net profit attributable to the parent company of 787 million yuan, up 9.8% year-on-year [1]. - The revenue from the lithium extraction project significantly declined, impacting the overall performance of the system equipment segment, while the adsorption materials business showed robust growth [2][3]. - The life sciences segment is expected to continue its growth trajectory, driven by the demand for high-quality solid-phase synthesis carriers and the performance of GLP-1 peptide drugs [3]. Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 662 million yuan, down 27.4% year-on-year, but up 10.89% quarter-on-quarter, with a net profit of 191 million yuan, down 4.0% year-on-year [1]. - For Q1 2025, the company reported a revenue of 577 million yuan, a decrease of 8.6% year-on-year and 12.91% quarter-on-quarter, while the net profit was 193 million yuan, an increase of 14.2% year-on-year [1]. Business Segments - The adsorption materials business generated 1.986 billion yuan in revenue, up 27.61% year-on-year, while the system equipment segment saw a revenue decline of 43.13% to 469 million yuan [2]. - The revenue from the lithium extraction system equipment was only 99 million yuan in 2024, a dramatic drop of 80.96% compared to 520 million yuan in 2023 [2]. Growth Areas - The life sciences segment's revenue reached 568 million yuan in 2024, reflecting a growth of 28% [3]. - The ultra-pure water segment achieved significant breakthroughs, with substantial orders from key semiconductor companies, indicating a growing market presence [3]. Profitability Forecast - The net profit forecasts for 2025-2027 are adjusted to 1.127 billion yuan, 1.463 billion yuan, and 1.706 billion yuan, respectively, maintaining the "Buy" rating [3].

Core Viewpoint - The company reported steady revenue and profit growth in 2024, with a notable performance in its core business segments, despite challenges in specific projects like the lithium extraction project [1][3]. Financial Performance Summary - In 2024, the company achieved revenue of 2.554 billion yuan, a year-on-year increase of 2.62%, and a net profit attributable to shareholders of 787 million yuan, up 9.79% year-on-year [1]. - The weighted average return on equity was 21.33%, down 1.79 percentage points year-on-year [1]. - The gross profit margin was 49.47%, an increase of 0.80 percentage points year-on-year, while the net profit margin was 31.11%, up 2.12 percentage points year-on-year [1]. - In Q4 2024, revenue was 662 million yuan, a year-on-year decrease of 27.40%, but a quarter-on-quarter increase of 10.89% [1]. - For Q1 2025, revenue was 577 million yuan, down 8.58% year-on-year and 12.91% quarter-on-quarter, while net profit was 193 million yuan, up 14.18% year-on-year [2]. Business Segment Performance - The lithium extraction project generated revenue of 99 million yuan in 2024, a significant decline of 80.96% year-on-year, primarily due to cyclical industry conditions and project execution delays [3]. - Excluding the lithium project, the core business achieved revenue of 2.455 billion yuan, a year-on-year increase of 24.71%, indicating strong growth momentum [3]. - Key segments such as water treatment and ultrapure water, life sciences, and metal resources reported revenues of 688 million, 568 million, and 256 million yuan, respectively, with year-on-year growth rates of 34%, 28%, and 30% [3]. - The chemical and catalysis, and food processing segments also showed strong performance, with revenues of 202 million and 56 million yuan, reflecting year-on-year increases of 42% and 28% [3]. Growth Drivers and Strategic Initiatives - The water treatment and ultrapure water business saw significant breakthroughs, with sales reaching 688 million yuan, a 34% increase year-on-year, driven by increased market penetration and long-term contracts with major clients [4]. - The life sciences segment is benefiting from the strong market performance of GLP-1 peptide drugs, leading to rapid growth in solid-phase synthesis carrier business [5]. - The company is expanding its international marketing and technical service network, enhancing its local team in North America and Europe, and investing in capacity expansion and upgrades to support long-term growth [5]. Profit Forecast and Valuation - The company is projected to achieve net profits of 1.026 billion, 1.283 billion, and 1.576 billion yuan for 2025-2027, with corresponding EPS of 2.02, 2.53, and 3.10 yuan [6]. - The current price corresponds to PE ratios of 22.85, 18.26, and 14.87 for the respective years, indicating a favorable long-term growth outlook [6].

Financial Performance - In 2024, the company achieved a revenue of CNY 2.55 billion, a year-on-year increase of 2.6%, and a net profit attributable to shareholders of CNY 0.98 billion, up 7.87% [2] - The large project revenue was CNY 0.1 billion, accounting for 3.9%, a significant decline of 81% compared to 2023, attributed to the cyclical nature of the lithium industry and project execution progress [3] - Excluding the large lithium project, the core business revenue was CNY 2.46 billion, a year-on-year increase of 25%, representing 96.1% of total revenue [3] - The comprehensive gross margin for 2024 was 49.5%, remaining stable compared to the previous year [3] - In Q1 2025, the company reported a revenue of CNY 0.577 billion, a decrease of 8% year-on-year, with a net profit of CNY 0.193 billion, an increase of 14% [3] Business Segments - The chemical and catalytic adsorption separation materials segment achieved sales revenue of CNY 0.202 billion in 2024, a year-on-year increase of 42% [5] - The water treatment and ultra-pure adsorption materials segment generated sales revenue of CNY 0.688 billion in 2024, a growth of 34% [9] - The company plans to increase production capacity for high-end materials, targeting a total production of 65,700 tons in 2024, a 33.4% increase year-on-year [6] Strategic Initiatives - The Tibet Jiezhe Chaka project utilizes a new environmentally friendly "zero-carbon" process, overcoming challenges related to high altitude and sensitive environments [4] - The company is expanding its solid-phase synthesis carrier business, benefiting from the growing market for GLP-1 peptide drugs [8] - A shareholder meeting approved plans for a new high-end materials manufacturing park, aiming to meet the demand for high-value adsorption separation materials [6] Dividend Policy - The company plans to distribute a total cash dividend of CNY 0.365 billion for the 2024 fiscal year, which represents 46% of the net profit attributable to shareholders [10]